Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03006146
Recruitment Status : Recruiting
First Posted : December 30, 2016
Last Update Posted : February 1, 2019
Sponsor:
Collaborators:
Rare Diseases Clinical Research Network
National Center for Advancing Translational Science (NCATS)
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati

Brief Summary:

Autoimmune PAP is a rare lung disease affecting less than 5,000 individuals in US with no FDA-approved pharmacologic therapy. Results from "off-label" use in case reports and clinical studies completed outside of the US indicate that inhaled rhGM-CSF may be a safe and effective thera-py for autoimmune PAP. Preliminary clinical trials of inhaled rhGM-CSF in autoimmune PAP patients show promising results, 62%-96% therapeutic response rate without any identifiable drug-related adverse effects in at least 73 autoimmune PAP patients. However, the pharmacokinetics (PK), pharmacodynamics (PD), optimal dose, and treatment duration to maximize efficacy are unknown.

The goal is to begin to address these knowledge gaps for inhaled sargramostim for autoimmune PAP patients with a pilot safety and PK/PD study (TPSC-110). TPSC-110, PharmPAP, which is a self-controlled open-label, phase I study to evaluate the safety, PK, and PD of inhaled sargra-mostim in autoimmune PAP patients. These results will impact the field by 1) confirming existing published data, 2) monitoring the local effects of inhaled sargramostim in autoimmune PAP patients, 3) potentially demonstrating a safe starting dose for a later trial to evaluate the therapeutic efficacy of inhaled sargramostim for autoimmune PAP.


Condition or disease Intervention/treatment Phase
Autoimmune Pulmonary Alveolar Proteinosis Drug: Sargramostim Phase 1

Detailed Description:

PAP is a rare syndrome of surfactant accumulation and resulting hypoxemic respiratory failure that occurs in a number of diseases classified pathogenically into three groups: primary PAP (caused by disruption of GM-CSF signaling - autoimmune PAP, hereditary PAP), secondary PAP (caused by reduction in alveolar macrophage numbers and/or functions), and surfactant dysfunction-related PAP (caused by mutations in genes required for normal surfactant production). In current clinical practice, PAP is diagnosed based on a lung biopsy; an approach that is not able to identify the etiology of the PAP. Current therapy involves the physical removal of surfactant by a procedure in which the lungs are repeatedly filled with saline and emptied - whole lung lavage, which is invasive, inefficient, and not widely available, especially for children. Importantly, research advances have elucidated the pathogenesis of diseases causing PAP in most patients and have identified new diagnostic and therapeutic approaches. Simple blood-based research tests can now identify the PAP-causing disease in about 95% of patients. Further, several promising potential disease-specific therapies are currently in development. Preliminary clinical trials of inhaled rhGM-CSF in autoimmune PAP patients show promising results, 62%-96% therapeutic response rate at two doses (250 and 500 mcg/day) without any identified safety concerns. At least 73 people with autoimmune PAP have been reported to have received inhaled sargramostim with no identified drug-related adverse effects. However, the PK, PD, optimal dose, and treatment duration needed to maximize efficacy are unknown. The short-term goal is to address knowledge gaps for inhaled sargramostim for autoimmune PAP patients in the following clinical study: a pilot safety and PK/PD study (TPSC-110). A major goal of this protocol is to evaluate the local and systemic safety, PK, and PD one dose of inhaled sargramostim in autoimmune PAP. The central hypothesis is that in patients with autoimmune PAP, aerosol inhalation of sargramostim will be well-tolerated and safe because the GM-CSF autoantibody will limit detection of free GM-CSF thereby preventing local and systemic toxicity. The specific objectives of this study are to: 1) evaluate the safety profile of one dose of inhaled sargramostim in patients with autoimmune PAP 2) estimate the PK profile of inhaled sargramostim following single dose administration in patients with autoimmune PAP 3) measure the PD effects of inhaled sargramostim following single dose administration in patients with autoimmune PAP.

The target population is adults with autoimmune PAP who have measurable, clinically significant disease satisfying all of the inclusion and exclusion criteria. The study design will involve recruitment, screening, and enrollment of participants into a phase I, open-label, multi-site study. Sargramostim will be administered to autoimmune PAP patients via aerosol inhalation one time at a dose of 125 mcg or 250 mcg. Adverse events (AEs), serious AEs (SAEs), PK, and PD parameters will be evaluated (see Appendix 3 Schedule of Events). The experimental approach will evaluate 1) safety of inhaled sargramostim by documenting occurrence of treatment-emergent AEs and SAEs, 2) PK profile of GM-CSF in serum and BAL fluid, 3) local and systemic PD effects of inhaled GM-CSF and 4) effects of inhaled GM-CSF on the quality of life for participants. Anticipated results will determine the safety profile of inhaled sargramostim in patients with autoimmune PAP, will evaluate total and free GM-CSF levels in blood and lung, effects of sargramostim on blood and BAL cell counts, differentials, baseline- and GM-CSF-responsiveness of blood leukocytes and BAL cells, and biomarkers of PAP in patients with autoimmune PAP after single dose administration. These results will impact the field by 1) confirming existing published data, 2) monitoring local effects of inhaled sargramostim in autoimmune PAP patients, 3) demonstrating a safe starting dose to evaluate the efficacy of inhaled sargramostim for autoimmune PAP.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Actual Study Start Date : July 13, 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sargramostim
Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
Drug: Sargramostim
Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
Other Names:
  • Leukine
  • recombinant human GM-CSF




Primary Outcome Measures :
  1. Occurrence of any treatment-emergent adverse events and serious adverse events [ Time Frame: 1 year ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0


Secondary Outcome Measures :
  1. Maximum plasma GM-CSF Concentration (Cmax) [ Time Frame: 1 year ]
    Maximum concentration of free and toal GM-CSF in the plasma following a single administration of inhaled sargramostim

  2. Time to maximum plasma GM-CSF concentration (TMax) [ Time Frame: 1 year ]
    Time to maximum plasma concentrations of free and total GM-CSF following a single administration of inhaled sargramostim

  3. GM-CSF Area Under the Curve (AUC) [ Time Frame: 1 year ]
    Systemic exposure to GM-CSF in plasma samples collected at regular intervals following a single administration of inhaled sargramostim

  4. Half-life of inhaled GM-CSF (t1/2) [ Time Frame: 1 year ]
    Half-life of GM-CSF following a single administration of inhaled sargramostim

  5. Complete cell counts and differentials in blood and BAL fluid [ Time Frame: 1 year ]
    Cell Counts and differentials in blood and BAL fluid following a single administration of inhaled sargramostim will be compared to baseline values (pre-study drug administration)

  6. GM-CSF autoantibody levels in blood and BAL fluid [ Time Frame: 1 year ]
    GM-CSF autoantibody concentrations in blood and BAL fluid following a single administration of inhaled sargramostim will be compared to baseline values (pre-study drug administration)

  7. GM-CSF signaling levels in blood and BAL fluid [ Time Frame: 1 year ]
    Responsiveness of blood and BAL cells to in vitro stimulation with GM-CSF in blood and BAL fluid following a single administration of inhaled sargramostim will be compared to baseline values (pre-study drug administration)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Male or female

Age ≥ 18 years and ≤ 80 years

Able to understand and willing to sign a written informed consent document

Able and willing to use hand held nebulizer

Able and willing to adhere to study visit schedule and study procedures

Diagnosis of autoimmune PAP determined by:

  • History of a diagnosis of PAP with or without supporting lung histology or BAL/cytology

and

  • Abnormal serum GM-CSF autoantibody test (GMAb ELISA Test)

and

  • Chest CT findings compatible with a diagnosis of autoimmune PAP

Evidence of impaired GM-CSF signaling demonstrated by an abnormal STAT5 phosphorylation index (STAT5-PI) test measured in heparinized whole blood at the time screening

A-aDO2 ≥ 15 mm Hg

Exclusion Criteria:

Diagnosis of any other PAP-causing disease

Autoimmune PAP complicated by:

  • Severe disease at screening/enrollment (A-aD02<50)
  • Clinically significant pulmonary fibrosis

History of any clinically significant:

  • Other lung disease
  • Cardiovascular disease
  • Disease requiring use of systemic steroids in past year
  • Coagulopathy or other hematologic disease
  • Active / serious lung or systemic infection
  • Persistent or unexplained fever >101oF within 2 months of study
  • Use of any immunosuppressive medication within 3-6 months of screening
  • Women who are pregnant or plan to become pregnant
  • History of active tobacco/e-cig/marijuana use
  • Concomitant or recent use of specific medicines

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03006146


Contacts
Layout table for location contacts
Contact: Bruce Trapnell 513-636-6361 Bruce.Trapnell@cchmc.og
Contact: Brenna Carey 513-636-8916 Brenna.Carey@cchmc.org

Locations
Layout table for location information
United States, California
University of California, Los Angeles Recruiting
Los Altos, California, United States, 90095
Contact: Tisha Wang         
Contact: Jamal Sharif    310-825-5316    JSharif@mednet.ucla.edu   
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Brenna Carey    513-636-8916    Brenna.Carey@cchmc.org   
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Rare Diseases Clinical Research Network
National Center for Advancing Translational Science (NCATS)
Investigators
Layout table for investigator information
Study Chair: Bruce Trapnell Children's Hospital Medical Center, Cincinnati

Layout table for additonal information
Responsible Party: Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier: NCT03006146     History of Changes
Other Study ID Numbers: TPSC-110
UL1TR001425 ( U.S. NIH Grant/Contract )
First Posted: December 30, 2016    Key Record Dates
Last Update Posted: February 1, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Alveolar Proteinosis
Autoimmune Diseases
Lung Diseases
Respiratory Tract Diseases
Immune System Diseases
Molgramostim
Sargramostim
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents